Regeneron beats quarterly profit estimates on Dupixent strength

Core Viewpoint - U.S. drugmaker Regeneron Pharmaceuticals exceeded analysts' profit expectations for the fourth quarter, driven by robust demand for its eczema treatment, Dupixent [1] Company Summary - Regeneron Pharmaceuticals reported a strong performance in the fourth quarter, attributed to the high demand for its eczema treatment, Dupixent [1]